Status:
COMPLETED
Clinical Trial of Levodopa/Carbidopa ( Sinemet) Therapy in Angel Man Syndrome
Lead Sponsor:
Bennett Lavenstein
Conditions:
Angelman Syndrome
Eligibility:
All Genders
18-16 years
Phase:
NA
Brief Summary
The purpose of this study is to evaluate the safety and effectiveness (how well a drug works) of Carbidopa/levodopa (Sinemet) in individuals with Angelman syndrome. Sinemet is a medication that helps ...
Detailed Description
Angelman syndrome (AS) is a well-recognized cause of disability in children who present with movement or balance disorder, usually ataxia and/or tremulous movement of the limbs, severe speech and cogn...
Eligibility Criteria
Inclusion
- Diagnosis of Angelman syndrome confirmed by molecular genetic testing.
- Age between 18 months and 16 years of age
- Absence of any contraindication to the use of Sinemet as determined by the PI
Exclusion
- Intractable epilepsy not responsive to anticonvulsive therapy in the patient with this syndrome.
- History of prior drug intolerances/drug hypersensitivity to any agent that may be similar to L Dopa .
- Progressively deteriorating EEG pattern.
Key Trial Info
Start Date :
November 26 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2019
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT03235037
Start Date
November 26 2013
End Date
February 1 2019
Last Update
April 22 2019
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.